These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 34033185)

  • 1. MRI quantitative susceptibility mapping of the substantia nigra as an early biomarker for Lewy body disease.
    Chen Q; Boeve BF; Forghanian-Arani A; Senjem ML; Jack CR; Przybelski SA; Lesnick TG; Kremers WK; Fields JA; Schwarz CG; Gunter JL; Trzasko JD; Graff-Radford J; Savica R; Knopman DS; Dickson DW; Ferman TJ; Graff-Radford N; Petersen RC; Kantarci K
    J Neuroimaging; 2021 Sep; 31(5):1020-1027. PubMed ID: 34033185
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exploring the Sensitivity of Prodromal Dementia with Lewy Bodies Research Criteria.
    Phillips JR; Matar E; Ehgoetz Martens KA; Moustafa AA; Halliday GM; Lewis SJG
    Brain Sci; 2022 Nov; 12(12):. PubMed ID: 36552054
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitative evaluation of iron content in idiopathic rapid eye movement sleep behavior disorder.
    Sun J; Lai Z; Ma J; Gao L; Chen M; Chen J; Fang J; Fan Y; Bao Y; Zhang D; Chan P; Yang Q; Ye C; Wu T; Ma T
    Mov Disord; 2020 Mar; 35(3):478-485. PubMed ID: 31846123
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantifying iron deposition within the substantia nigra of Parkinson's disease by quantitative susceptibility mapping.
    An H; Zeng X; Niu T; Li G; Yang J; Zheng L; Zhou W; Liu H; Zhang M; Huang D; Li J
    J Neurol Sci; 2018 Mar; 386():46-52. PubMed ID: 29406966
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantitative Susceptibility Mapping in Parkinson's Disease.
    Langkammer C; Pirpamer L; Seiler S; Deistung A; Schweser F; Franthal S; Homayoon N; Katschnig-Winter P; Koegl-Wallner M; Pendl T; Stoegerer EM; Wenzel K; Fazekas F; Ropele S; Reichenbach JR; Schmidt R; Schwingenschuh P
    PLoS One; 2016; 11(9):e0162460. PubMed ID: 27598250
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lateral Asymmetry and Spatial Difference of Iron Deposition in the Substantia Nigra of Patients with Parkinson Disease Measured with Quantitative Susceptibility Mapping.
    Azuma M; Hirai T; Yamada K; Yamashita S; Ando Y; Tateishi M; Iryo Y; Yoneda T; Kitajima M; Wang Y; Yamashita Y
    AJNR Am J Neuroradiol; 2016 May; 37(5):782-8. PubMed ID: 26822728
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic imaging of dementia with Lewy bodies by susceptibility-weighted imaging of nigrosomes versus striatal dopamine transporter single-photon emission computed tomography: a retrospective observational study.
    Kamagata K; Nakatsuka T; Sakakibara R; Tsuyusaki Y; Takamura T; Sato K; Suzuki M; Hori M; Kumamaru KK; Inaoka T; Aoki S; Terada H
    Neuroradiology; 2017 Jan; 59(1):89-98. PubMed ID: 28035426
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differentiating Prodromal Dementia with Lewy Bodies from Prodromal Alzheimer's Disease: A Pragmatic Review for Clinicians.
    Wyman-Chick KA; Chaudhury P; Bayram E; Abdelnour C; Matar E; Chiu SY; Ferreira D; Hamilton CA; Donaghy PC; Rodriguez-Porcel F; Toledo JB; Habich A; Barrett MJ; Patel B; Jaramillo-Jimenez A; Scott GD; Kane JPM
    Neurol Ther; 2024 Jun; 13(3):885-906. PubMed ID: 38720013
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Decreased striatal dopamine transporter uptake and substantia nigra hyperechogenicity as risk markers of synucleinopathy in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a prospective study [corrected].
    Iranzo A; Lomeña F; Stockner H; Valldeoriola F; Vilaseca I; Salamero M; Molinuevo JL; Serradell M; Duch J; Pavía J; Gallego J; Seppi K; Högl B; Tolosa E; Poewe W; Santamaria J;
    Lancet Neurol; 2010 Nov; 9(11):1070-7. PubMed ID: 20846908
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Associations of quantitative susceptibility mapping with Alzheimer's disease clinical and imaging markers.
    Cogswell PM; Wiste HJ; Senjem ML; Gunter JL; Weigand SD; Schwarz CG; Arani A; Therneau TM; Lowe VJ; Knopman DS; Botha H; Graff-Radford J; Jones DT; Kantarci K; Vemuri P; Boeve BF; Mielke MM; Petersen RC; Jack CR
    Neuroimage; 2021 Jan; 224():117433. PubMed ID: 33035667
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Longitudinal evolution of cortical thickness signature reflecting Lewy body dementia in isolated REM sleep behavior disorder: a prospective cohort study.
    Shin JH; Kim H; Kim YK; Yoon EJ; Nam H; Jeon B; Lee JY
    Transl Neurodegener; 2023 May; 12(1):27. PubMed ID: 37217951
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical and pathologic features of two groups of patients with dementia with Lewy bodies: effect of coexisting Alzheimer-type lesion load.
    Del Ser T; Hachinski V; Merskey H; Munoz DG
    Alzheimer Dis Assoc Disord; 2001; 15(1):31-44. PubMed ID: 11236823
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship of substantia nigra hyperechogenicity to risk of Lewy body disease in idiopathic REM sleep behavior disorder patients: a longitudinal study.
    Miyamoto M; Miyamoto T
    Sleep Med; 2020 Apr; 68():31-34. PubMed ID: 32018190
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Susceptibility Magnetic Resonance Imaging Correlates with Glial Density and Tau in the Substantia Nigra Pars Compacta.
    Wang EW; Brown GL; Lewis MM; Jellen LC; Pu C; Johnson ML; Chen H; Kong L; Du G; Huang X
    Mov Disord; 2023 Mar; 38(3):464-473. PubMed ID: 36598274
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Imaging of nigrosome 1 in substantia nigra at 3T using multiecho susceptibility map-weighted imaging (SMWI).
    Nam Y; Gho SM; Kim DH; Kim EY; Lee J
    J Magn Reson Imaging; 2017 Aug; 46(2):528-536. PubMed ID: 27859983
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Spatiotemporal changes in substantia nigra neuromelanin content in Parkinson's disease.
    Biondetti E; Gaurav R; Yahia-Cherif L; Mangone G; Pyatigorskaya N; Valabrègue R; Ewenczyk C; Hutchison M; François C; Arnulf I; Corvol JC; Vidailhet M; Lehéricy S
    Brain; 2020 Sep; 143(9):2757-2770. PubMed ID: 32856056
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prodromal Dementia With Lewy Bodies: Clinical Characterization and Predictors of Progression.
    van de Beek M; van Steenoven I; van der Zande JJ; Barkhof F; Teunissen CE; van der Flier WM; Lemstra AW
    Mov Disord; 2020 May; 35(5):859-867. PubMed ID: 32048343
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Magnetic Resonance Imaging Biomarkers to Assess Substantia Nigra Damage in Idiopathic Rapid Eye Movement Sleep Behavior Disorder.
    Pyatigorskaya N; Gaurav R; Arnaldi D; Leu-Semenescu S; Yahia-Cherif L; Valabregue R; Vidailhet M; Arnulf I; Lehéricy S
    Sleep; 2017 Nov; 40(11):. PubMed ID: 28958075
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Whole brain pattern of iron accumulation in REM sleep behavior disorder.
    Varga Z; Keller J; Robinson SD; Serranova T; Nepozitek J; Zogala D; Trnka J; Ruzicka E; Sonka K; Dusek P
    Hum Brain Mapp; 2024 Apr; 45(5):e26675. PubMed ID: 38590155
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neurodegenerative disease status and post-mortem pathology in idiopathic rapid-eye-movement sleep behaviour disorder: an observational cohort study.
    Iranzo A; Tolosa E; Gelpi E; Molinuevo JL; Valldeoriola F; Serradell M; Sanchez-Valle R; Vilaseca I; Lomeña F; Vilas D; Lladó A; Gaig C; Santamaria J
    Lancet Neurol; 2013 May; 12(5):443-53. PubMed ID: 23562390
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.